ClinicalTrials.gg
Not yet recruitingNCT06611514PROPOSEUpdated Nov 19, 2024

Effect of Intravaginal Prasterone on Symptoms of Genitourinary Syndrome of Menopause (GSM) in Women in Menopause With Previous Breast Cancer

A Phase 3 interventional study of Prasterone (DHEA) in Women With Breast Cancer, sponsored by European Institute of Oncology. Not yet recruiting at 1 site in Italy. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-19.

Sponsored by European Institute of Oncology · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
95
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies testing dehydroepiandrosterone in Breast Neoplasms — 1 open to participants now, 1 under way, 1 of them phase 3. Dehydroepiandrosterone · Breast Neoplasms.

Planned enrollment
2nd of 10
95 · median 9
Started
2024
the only one that year
Phase 3
3 of 10
1 open now
Registered
10th of 10
by date
Lead sponsor
1 of 10
European Institute of Oncology

Among the 10 studies testing dehydroepiandrosterone in Breast Neoplasms, this one is the 2nd largest by planned enrollment, is the only one that started in 2024, is one of 3 in phase 3, and was the 10th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

1 of the 10 studies testing dehydroepiandrosterone in Breast Neoplasms is open now, in 1 country.

By country, each count listing its studies:

Where they have run

About dehydroepiandrosterone

Dehydroepiandrosterone: first FDA approval 2016 (INTRAROSA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing dehydroepiandrosterone in Breast Neoplasms, or all of them as a file.
02

Study summary

The goal of this interventional study is to evaluate the effect of Intravaginal Prasterone for the treatment of moderate to severe symptoms of genitourinary syndrome (GSM) due to natural, surgical or treatment-induced menopause and the effect on the quality of life, including sexual function and mood well-being, in women with Breast Cancer. A sample size of 95 patients will be needed to show that the proportion of women showing symptom improvement is greater than 50%. Subjects will be followed up at four weeks and twelve weeks of treatment. One and three-month outcomes will be provided after the end of treatment. Comparison between menopausal women with previous breast cancer that have finished hormonal therapy or with ER negative breast cancer and women currently under endocrine therapy with AIs will be performed.

03

Conditions studied

  • Women With Breast Cancer

Browse trials for

Keywords

  • genitourinary syndrome
  • prasterone
  • breast cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed breast cancer, completely excised
  • Natural or iatrogenic menopausal status
  • No evidence of distant
  • Self-identified moderate to severe symptoms of genitourinary syndrome
  • Normal kidney and liver function
  • Written signed and dated by patient
  • Negative Papanicolau (Pap) Smear Cytology Test within 1 year prior to enrollment

Exclusion criteria

Exclusion Criteria:

  • Vaginal or uterine bleeding of unknown origin
  • Current diagnosis of any non-breast
  • disease
  • Currently on chemiotherapy
  • Currently on treatment with tamoxifen
  • Mentally incompetent or evidence of active substance or alcohol abuse
  • Endometrial hyperplasia
  • Pregnancy or lactation
  • Currently use of other vaginal therapy for the same purpose (if present, they have to be stopped 15 days before baseline visit)
  • metabolic or endocrine disease not controlled by medication
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
95 participants (estimated)

Study arms

  • Experimental
    intravaginal Prasterone

    Drug: Prasterone (DHEA)

Interventions

06

What researchers measure

Primary outcomes

  1. Establish subjective improvement in genitourinary symptomatology at intervals marked by the study

    To establish the improvement in vulvovaginal and urinary symptoms, by subjective evaluation at baseline, at 12 weeks and after 1 and 3 months after the end of the treatment. Establish tissue trophism improvement through gynecological evaluation, the use of validated scales (Vaginal Health Index), and determination of the maturation index on vaginal spatula, measure serum estradiol during and after treatment

    Time frame: From enrollment to after 3 months after the end of treatment

  2. evaluation of vulvovaginal and urinary symptoms

    evaluation of vaginal dryness, dyspareunia, pruritis, burning and dysuria with a 0 to 4 score (0: absence, 1: mild, 2: moderate, 3: severe, 4: very severe)

    Time frame: 6 months

  3. improvement in vaginal signs

    To establish the improvement in vaginal signs using the Vaginal Health Index Scale (VHI)

    Time frame: 6 months

  4. evaluation fo maturation index

    To assess the maturation index (as percentage of superficial, intermediate and parabasal cells) in the vaginal mucosa

    Time frame: 6 months

  5. grade of satisfaction

    To report the grade of satisfaction as measured by the Global Response Assessment at the end of the study

    Time frame: 6 months

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2024; primary completion for Jan 2027, 25 months later.

Of 328 non-industry phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 127. This study's planned 25 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2024
First posted
Sep 25, 2024
StartEst.
Dec 1, 2024
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 1, 2027
Last update
Nov 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06611514
Responsible party
Sponsor
First posted
Sep 25, 2024
Start date
Dec 1, 2024 (estimated)
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Nov 19, 2024

Study contacts

SILVIA MARTELLA
Contact
silvia.martella@ieo.it
0039 02 943742104
SILVIA MARTELLA
principal investigator · European Institue of Oncology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dehydroepiandrosterone

Start the discussion